Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated. We conducted a phase II trial in patients with melanoma whose tumors harbored a BRAF mutation. Patients were stratified...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2013-04, Vol.19 (8), p.2257-2264
Hauptverfasser:	CATALANOTTI, Federica, SOLIT, David B, SCHWARTZ, Gary K, ROSEN, Neal, CHAPMAN, Paul B, PULITZER, Melissa P, BERGER, Michael F, SCOTT, Sasinya N, IYRIBOZ, Tunc, LACOUTURE, Mario E, PANAGEAS, Katherine S, WOLCHOK, Jedd D, CARVAJAL, Richard D
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents Benzimidazoles - administration & dosage Benzimidazoles - adverse effects Benzimidazoles - therapeutic use Biological and medical sciences Cohort Studies Dermatology Disease-Free Survival Drug Administration Schedule Exanthema - chemically induced Female Humans Lymphopenia - chemically induced Male Medical sciences Melanoma - drug therapy Melanoma - genetics Melanoma - metabolism Middle Aged Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinase Kinases - metabolism Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Pharmacology. Drug treatments Phosphatidylinositol 3-Kinases - metabolism Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects Treatment Outcome Tumors Tumors of the skin and soft tissue. Premalignant lesions Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!